Menu
GWAS Study

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW et al.

28736931 PubMed ID
GWAS Study Type
1264 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RD
Rotroff DM
PS
Pijut SS
MS
Marvel SW
JJ
Jack JR
HT
Havener TM
PA
Pujol A
SA
Schluter A
GG
Graf GA
GH
Ginsberg HN
SH
Shah HS
GH
Gao H
MM
Morieri ML
DA
Doria A
MJ
Mychaleckyi JC
MH
McLeod HL
BJ
Buse JB
WM
Wagner MJ
MA
Motsinger-Reif AA
Chapter II

Abstract

Summary of the research findings

Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular disease. Fibrates are a class of drugs prescribed to treat dyslipidemia, but variation in response has been observed. To evaluate common and rare genetic variants that impact lipid responses to fenofibrate in statin-treated patients with T2D, we examined lipid changes in response to fenofibrate therapy using a genomewide association study (GWAS). Associations were followed-up using gene expression studies in mice. Common variants in SMAD3 and IPO11 were marginally associated with lipid changes in black subjects (P < 5 × 10-6 ). Rare variant and gene expression changes were assessed using a false discovery rate approach. AKR7A3 and HSD17B13 were associated with lipid changes in white subjects (q < 0.2). Mice fed fenofibrate displayed reductions in Hsd17b13 gene expression (q < 0.1). Associations of variants in SMAD3, IPO11, and HSD17B13, with gene expression changes in mice indicate that transforming growth factor-beta (TGF-β) and NRF2 signaling pathways may influence fenofibrate effects on dyslipidemia in patients with T2D.

781 European ancestry individuals, 138 African American ancestry individuals, 345 unknown ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

1264
Total Participants
GWAS
Study Type
No
Replicated
African American or Afro-Caribbean, European
Ancestry
Canada, U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.